1.40
price down icon8.50%   -0.13
after-market Dopo l'orario di chiusura: 1.35 -0.05 -3.57%
loading
Precedente Chiudi:
$1.53
Aprire:
$1.51
Volume 24 ore:
378.73K
Relative Volume:
0.72
Capitalizzazione di mercato:
$64.49M
Reddito:
-
Utile/perdita netta:
$-31.39M
Rapporto P/E:
-1.6867
EPS:
-0.83
Flusso di cassa netto:
$-18.45M
1 W Prestazione:
+18.64%
1M Prestazione:
+77.55%
6M Prestazione:
+42.12%
1 anno Prestazione:
+48.29%
Intervallo 1D:
Value
$1.40
$1.545
Intervallo di 1 settimana:
Value
$1.228
$1.79
Portata 52W:
Value
$0.5116
$1.79

Quince Therapeutics Inc Stock (QNCX) Company Profile

Name
Nome
Quince Therapeutics Inc
Name
Telefono
415-910-5717
Name
Indirizzo
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Name
Dipendente
32
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-12
Name
Ultimi documenti SEC
Name
QNCX's Discussions on Twitter

Quince Therapeutics Inc Borsa (QNCX) Ultime notizie

pulisher
Oct 31, 2024

Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com

Oct 29, 2024
pulisher
Oct 29, 2024

Rodman & Renshaw Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN

Oct 29, 2024
pulisher
Oct 23, 2024

Quince Therapeutics shares rated Buy at EF Hutton, optimistic about EryDex's potential - Investing.com Canada

Oct 23, 2024
pulisher
Oct 22, 2024

EF Hutton Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN

Oct 22, 2024
pulisher
Oct 14, 2024

Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire

Oct 14, 2024
pulisher
Sep 25, 2024

Quince Therapeutics (NASDAQ:QNCX) Shares Down 5.1% - Defense World

Sep 25, 2024
pulisher
Sep 20, 2024

Finalist, Public Company, Medium: Christopher J. Senner, Exelixis Inc. - The Business Journals

Sep 20, 2024
pulisher
Sep 12, 2024

Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR

Sep 12, 2024
pulisher
Sep 04, 2024

Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 Shares - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

Quince Therapeutics CEO acquires $107k in company stock - Investing.com

Sep 03, 2024
pulisher
Sep 03, 2024

Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Sep 03, 2024
pulisher
Sep 02, 2024

The Potential Rise in the Price of Quince Therapeutics Inc (QNCX) following insiders activity - Knox Daily

Sep 02, 2024
pulisher
Sep 02, 2024

Healthy Upside Potential: Quince Therapeutics Inc (QNCX) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Have you been able to find a good deal on Quince Therapeutics Inc’s shares? - US Post News

Sep 02, 2024
pulisher
Aug 24, 2024

Charles S. Ryan Purchases 48,387 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World

Aug 24, 2024
pulisher
Aug 23, 2024

Brendan Hannah Buys 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World

Aug 23, 2024
pulisher
Aug 21, 2024

Quince Therapeutics COO Brendan Hannah buys $24,166 in company stock - Investing.com

Aug 21, 2024
pulisher
Aug 21, 2024

QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - MSN

Aug 21, 2024
pulisher
Aug 19, 2024

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha

Aug 19, 2024
pulisher
Aug 17, 2024

Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

Quince reports data from Phase III Ataxia-Telangiectasia treatment trial - Clinical Trials Arena

Aug 16, 2024
pulisher
Aug 15, 2024

Phase III data on Quince Therapeutics’ EryDex - The Pharma Letter

Aug 15, 2024
pulisher
Aug 15, 2024

Quince Therapeutics reports progress in A-T treatment study - Investing.com

Aug 15, 2024
pulisher
Aug 15, 2024

Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) - StockTitan

Aug 15, 2024
pulisher
Aug 14, 2024

Quince Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle

Aug 14, 2024
pulisher
Aug 14, 2024

Market Resilience: Quince Therapeutics Inc (QNCX) Finishes Weak at 0.58, Down -16.54 - The Dwinnex

Aug 14, 2024
pulisher
Aug 13, 2024

Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results - StockTitan

Aug 13, 2024
pulisher
Jul 26, 2024

Quince Therapeutics (NASDAQ:QNCX) Trading Up 2.6% - Defense World

Jul 26, 2024
pulisher
Jul 07, 2024

Reviewing Genenta Science (NASDAQ:GNTA) & Quince Therapeutics (NASDAQ:QNCX) - Defense World

Jul 07, 2024
pulisher
Jun 26, 2024

Quince Therapeutics doses first subject in Ataxia-Telangiectasia trial - Clinical Trials Arena

Jun 26, 2024
pulisher
Jun 25, 2024

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia ... - Business Wire

Jun 25, 2024
pulisher
Jun 25, 2024

Quince Therapeutics (NASDAQ:QNCX) versus Kymera Therapeutics (NASDAQ:KYMR) Critical Review - Defense World

Jun 25, 2024
pulisher
Jun 25, 2024

Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia - Yahoo Finance

Jun 25, 2024
pulisher
Jun 22, 2024

Quince Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Jun 22, 2024
pulisher
Jun 21, 2024

Quince Therapeutics faces Nasdaq delisting over share price - Investing.com

Jun 21, 2024
pulisher
Jun 19, 2024

Stock Surge: Quince Therapeutics Inc (QNCX) Closes at 0.68, Marking a -4.23 Increase/Decrease – DWinneX - The Dwinnex

Jun 19, 2024
pulisher
Jun 17, 2024

Critical Review: Autolus Therapeutics (NASDAQ:AUTL) and Quince Therapeutics (NASDAQ:QNCX) - Defense World

Jun 17, 2024
pulisher
Jun 14, 2024

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results - br.ADVFN.com

Jun 14, 2024
pulisher
Jun 09, 2024

O-I Glass, Inc. (NYSE:OI) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Jun 09, 2024
pulisher
Jun 09, 2024

Comparing Ikena Oncology (NASDAQ:IKNA) & Quince Therapeutics (NASDAQ:QNCX) - Defense World

Jun 09, 2024
pulisher
Jun 07, 2024

ChromaDex wins orphan designation for rare ataxia drug - Pharmaceutical Technology

Jun 07, 2024
pulisher
Jun 04, 2024

FDA fast tracks Quince Therapeutics’ rare ataxia drug EryDex - Pharmaceutical Technology

Jun 04, 2024
pulisher
Jun 04, 2024

Quince Therapeutics (NASDAQ:QNCX) Trading 5.7% Higher - Defense World

Jun 04, 2024
pulisher
Jun 04, 2024

Ascend Wellness (OTC:AAWH) Shares Down 6.5% - Defense World

Jun 04, 2024
pulisher
Jun 04, 2024

Short Interest in bioAffinity Technologies, Inc. (NASDAQ:BIAF) Rises By 7.1% - Defense World

Jun 04, 2024
pulisher
Jun 04, 2024

Mandalay Resources (OTCMKTS:MNDJF) Stock Price Down 3% - Defense World

Jun 04, 2024
pulisher
Jun 03, 2024

FDA fast tracks Quince Therapeutics' EryDex for A-T treatment - Investing.com South Africa

Jun 03, 2024
pulisher
Jun 03, 2024

FDA fast tracks Quince Therapeutics' EryDex for A-T treatment By Investing.com - Investing.com

Jun 03, 2024
pulisher
Jun 03, 2024

Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System - StockTitan

Jun 03, 2024

Quince Therapeutics Inc Azioni (QNCX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Quince Therapeutics Inc Azioni (QNCX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Thye Dirk
CEO AND CHIEF MEDICAL OFFICER
Aug 29 '24
Buy
0.69
77,500
53,475
766,941
Ryan Charles S.
PRESIDENT
Aug 20 '24
Buy
0.65
48,387
31,452
122,461
Hannah Brendan
CHIEF BUSINESS OFFICER AND COO
Aug 21 '24
Buy
0.63
30,845
19,337
296,540
Hannah Brendan
CHIEF BUSINESS OFFICER AND COO
Aug 20 '24
Buy
0.60
5,924
3,579
265,695
Hannah Brendan
CHIEF BUSINESS OFFICER AND COO
Aug 19 '24
Buy
0.58
2,155
1,250
259,771
Hannah Brendan
CHIEF BUSINESS OFFICER AND COO
Jun 04 '24
Option Exercise
0.55
56,061
30,834
257,616
Thye Dirk
CHIEF EXECUTIVE OFFICER
Jan 16 '24
Option Exercise
0.79
240,530
190,791
689,441
Lamond David
Director
Dec 14 '23
Buy
1.04
22,627
23,532
2,347,545
Lamond David
Director
Dec 12 '23
Buy
1.02
22,327
22,774
2,302,291
Lamond David
Director
Dec 13 '23
Buy
1.00
22,627
22,627
2,324,918
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):